Clinical Trial Update: M6620 Plus Standard Treatment in Oesophageal and Other Cancer [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating M6620 in combination with standard treatment for esophageal cancer (esophageal adenocarcinoma and esophageal squamous cell carcinoma) h…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Adenocarcinoma
• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• M6620 (berzosertib)

Snippet

Sponsor: University of Oxford | Conditions: Oesophageal Adenocarcinoma, Squamous Cell Carcinoma | Phase 1 | Status: COMPLETED | Results posted: 2024-07-18